Aging is associated with gradual changes in liver structure and function and various changes in liver cells, including hepatic sinusoidal endothelial cells. Aging can also increase the risk of various liver diseases and acts as an adverse prognostic factor leading to an increase in mortality. Drug development for aging-related liver diseases holds promise for improving outcomes and quality of life for elderly patients.
CD BioSciences provides preclinical contract research services specializing in aging-related liver disease research and drug development. With years of industry expertise, we are committed to providing high-quality and comprehensive research and development (R&D) services to advance our understanding of aging-related liver diseases and develop innovative therapeutic solutions.
At CD BioSciences, we recognize that aging-related liver diseases encompass a diverse range of conditions. We offer specialized R&D services tailored to each disease type, enabling a comprehensive and targeted approach to research and drug development.
We offer a comprehensive range of R&D services to investigate NAFLD and develop potential therapeutic targets. Furthermore, we conduct drug development studies in animal models to identify these targets and perform preclinical research.
Our services include customizing disease models for preclinical studies of ALD, identifying the molecular pathways involved in disease progression, identifying potential therapeutic targets, and developing drugs.
We offer specialized R&D services to help clients understand the mechanisms of liver fibrosis and develop effective anti-fibrotic therapies.
We offer comprehensive biomarker identification services to facilitate the development of reliable diagnostic tools for aging-related liver diseases. Our expert team utilizes advanced techniques such as high-throughput screening, proteomics, and metabolomics to identify and validate potential biomarkers. We aim to discover novel biomarkers that can improve disease detection, predict disease progression, and monitor treatment response.
CD BioSciences offers customized disease model customization services to meet specific research needs and accelerate drug discovery and development efforts. Our team has extensive experience in establishing in vitro cell culture systems and animal models that faithfully recapitulate the pathophysiological features of aging-related liver diseases.
CD BioSciences is committed to driving the discovery and development of novel therapeutics for aging-related liver diseases. Our comprehensive drug discovery and development services encompass hit identification, optimization, and preclinical assessment. Using a multidisciplinary approach, we employ innovative screening platforms, medicinal chemistry strategies, and preclinical efficacy and safety assessments to identify and optimize potential therapeutic targets.
Our company provides R&D services for healthcare products based on nutrients such as aspartic acid, ornithine, methionine, lycopene, and others to repair damaged and aged liver cells. Additionally, we offer animal models of aging-related liver diseases to evaluate the efficacy and safety of healthcare products. Our services also include conducting safety and toxicity studies to evaluate the potential adverse effects of healthcare products. We aim to improve healthy lifespan and prevent liver diseases associated with aging.
CD BioSciences is dedicated to advancing the understanding and treatment of aging-related liver diseases through our comprehensive range of R&D services. If you are interested in our services, please feel free to contact us or make an online inquiry.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.